Sarilumab
Sarilumab
Sarilumab (pronounced sah-rih-loo-mab) is a biologic drug used in the treatment of rheumatoid arthritis. It is a human monoclonal antibody that binds to the interleukin-6 receptor (IL-6R), inhibiting the pro-inflammatory activities of interleukin-6 (IL-6).
Etymology
The name "Sarilumab" is derived from a combination of syllables that reference its function and origin. "Sari" is a prefix used in pharmacology to denote synthetic antibodies, "lu" refers to the human origin of the drug, and "mab" is a common suffix for monoclonal antibodies.
Mechanism of Action
Sarilumab works by binding to the IL-6R, which is found on the surface of many cell types, including immune cells. By blocking the receptor, Sarilumab prevents IL-6 from binding and triggering the inflammatory response that contributes to rheumatoid arthritis symptoms.
Related Terms
- Biologic drug: A type of drug that is derived from living organisms or contain components of living organisms.
- Monoclonal antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells.
- Interleukin-6 receptor: A type of protein found on the surface of cells that binds to interleukin-6.
- Interleukin-6: A type of cytokine, a small protein that is important in cell signaling in immune response.
- Rheumatoid arthritis: A chronic inflammatory disorder affecting many joints, including those in the hands and feet.
External links
- Medical encyclopedia article on Sarilumab
- Wikipedia's article - Sarilumab
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski